3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Breast Neoplasms
22
Prostatic Neoplasms
21
Glioblastoma
19
Lung Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Rectal Neoplasms
12
Glioma
12
Neoplasms
11
Oropharyngeal Neoplasms
10
Head and Neck Neoplasms
10
Esophageal Neoplasms
8
Astrocytoma
8
Sarcoma
7
Neoplasm Metastasis
7
Uterine Cervical Neoplasms
6
Urinary Bladder Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Colorectal Neoplasms
6
Carcinoma, Squamous Cell
6
Brain Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Lymphoma, Follicular
5
Hodgkin Disease
5
Gliosarcoma
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Burkitt Lymphoma
5
Interventions
pembrolizumab
53
Paclitaxel
20
Cisplatin
15
Carboplatin
15
lenvatinib
10
Docetaxel
9
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Radiotherapy
×
90 days
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled